Myopia & Presbyopia Treatment Market - Global Forecast 2025-2032

The myopia and presbyopia treatment market is undergoing significant evolution, driven by demographic changes, adoption of advanced technologies, and ongoing innovation in clinical protocols. These shifts are prompting stakeholders to revisit strategies and deliver more integrated, patient-centric vision care solutions.

Market Snapshot: Myopia & Presbyopia Treatment Market Size and Trajectory

The global myopia and presbyopia treatment market grew from USD 22.14 billion in 2024 to USD 24.13 billion in 2025 and is projected to reach USD 45.77 billion by 2032, reflecting a CAGR of 9.49%. This expansion is underpinned by increasing cases of refractive errors, greater awareness among aging populations, and accelerated adoption of digital vision correction and diagnostic technologies. Stakeholders are adapting swiftly as the industry shifts toward outcome-focused solutions and coordinated patient care.

Scope & Segmentation of the Myopia and Presbyopia Treatment Market

This report provides comprehensive coverage of the market with a focus on segmentation, technology advancements, and key geographical regions:

• Treatment Types: Cataract surgery, corrective lenses (contact lenses, eyeglasses, multifocal lenses, orthokeratology lenses), implantable lenses, surgical treatments.
• Age Groups: Adults, middle-aged, older adults, pediatric patients.
• Disease Types: Myopia treatment, presbyopia treatment.
• Distribution Channels: Offline (hospitals, optical stores, specialty clinics), online platforms.
• Regional Scope: Americas (North America, Latin America), Europe, Middle East & Africa (UK, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, UAE, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
• Key Industry Players: ABB Optical Group, AbbVie Inc., AccuLens, Alcon Inc., ARCTIC VISION HONG KONG BIOTECH LIMITED, Bausch & Lomb Incorporated, Carl Zeiss AG, EssilorLuxottica, Euclid Systems Corporation, Eyenovia Inc., Haag-Streit Group, HOYA Vision Care Europe Hoya Holdings N.V., Johnson & Johnson Vision Care Inc., LENZ Therapeutics Inc., Menicon Co. Ltd., NIDEK CO. LTD., Orasis Pharmaceuticals Ltd, Regeneron Pharmaceuticals Inc., SCHWIND eye-tech-solutions GmbH, Sydnexis Inc., The Cooper Companies Inc., Topcon Corporation, Ziemer Ophthalmic Systems AG.
• Technologies and Approaches: Optical coherence tomography, wavefront aberrometry, digital health monitoring apps, automated refraction, teleoptometry.

Key Takeaways: Executive Insights for Senior Leaders

• Healthcare systems and optical providers are integrating advanced diagnostics with primary care to improve early detection and management of refractive errors.
• The transition toward value-based and bundled service models is enhancing accessibility and protecting patients from fluctuating pricing, especially as procurement strategies localize.
• Personalized treatments are in higher demand as patients expect more transparent outcomes and tailored vision correction options, prompting ecosystem collaboration across payers, technology providers, and clinician networks.
• New US tariff regulations in 2025 are prompting regional manufacturing and supply chain reconfiguration, impacting sourcing contracts and pricing models for device and pharmaceutical suppliers.
• Strategic alliances—including technology integrations and expanded clinical trial partnerships—are enabling manufacturers to capture specialized competencies and broaden their portfolios in fast-growing categories.
• Emerging business models, such as teleoptometry and direct-to-consumer channels, are gaining traction in under-served and remote markets, particularly throughout Asia-Pacific and regions prioritizing preventive eye health.

Tariff Impact: Navigating Pricing and Supply Chain Volatility

Recent US tariff changes have introduced cost pressures for manufacturers and suppliers, driving a shift toward regional production and alternative sourcing strategies across global supply chains. Companies are renegotiating supplier contracts and adjusting market entry strategies, while payers are advocating for service models that minimize end-user price shocks. These dynamics require ongoing vigilance, operational agility, and proactive engagement with customs and regulatory bodies.

Methodology & Data Sources

This analysis uses a robust methodological framework combining primary interviews with key stakeholders—including clinicians, manufacturers, and payers—alongside comprehensive review of peer-reviewed literature, regulatory data, and industry publications. Quantitative modeling, regression analysis, and scenario assessments underpin the reliability and strategic value of the forecast and insights.

Why This Report Matters for Decision-Makers

• Identifies actionable trends and innovations across treatment modalities and regional markets, supporting commercial and operational strategies.
• Assesses the evolving impact of policy, regulatory, and tariff changes on procurement, pricing, and market access.
• Equips leaders with practical intelligence for aligning product, partnership, and go-to-market initiatives against emerging growth opportunities and patient needs.

Conclusion

As refractive disorder care evolves, organizations that leverage scientific advancements, digital engagement, and integrated partnerships will position themselves for enduring growth. Aligning strategies with shifting clinical, operational, and policy landscapes remains essential for delivering enhanced patient outcomes and realizing full market potential.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.